A commentary notes that from a safety perspective, ferroquine— like chloroquine, amodiaquine, and piperaquine—does cause QTc prolongation and also shows some transient hepatic signals at higher doses; such risks need to be thoroughly assessed in further studies. However, unlike some artemisinin-based combination therapies in use, neither its maximum serum concentration or area under the curve are altered by food. In addition, it has never been deployed as monotherapy, and has no pre-existing cross-resistances against other medicines. Its activity against the parasites that are resistant to second-generation chloroquines such as amodiaquine and piperaquine will need to be continually monitored and confirmed.